About the Company
keros therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. the company's lead protein therapeutic product candidate is ker-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or mds, and in patients with myelofibrosis. it is also developing small molecule product candidate ker-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or fop, and is currently in a phase 1 clinical trial; and ker-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or pah. the company was founded i
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $KROS News
KROS Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the ...
Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable
Keros Therapeutics, Inc. (KROS) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for "trend" investors.
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical ...
Analysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX), Iridex (IRIX) and Keros Therapeutics (KROS)
CFA covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Apogee Therapeutics, Inc., and Dianthus Therapeutics ... from Truist Financial assigned a Buy rating to Keros ...
Keros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023
Warning! GuruFocus has detected 3 Warning Signs with KROS. On February 28, 2024, Keros Therapeutics Inc (NASDAQ:KROS) released its 8-K filing, detailing the company's financial results for the ...
Keros Therapeutics Inc KROS
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Keros Therapeutics Inc reports results for the quarter ended in December - Earnings Summary 28.02. Keros Therapeutics GAAP EPS of -$1.34 beats by $0.04, revenue of $0.14M ...
Keros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023
Warning! GuruFocus has detected 3 Warning Signs with KROS. On February 28, 2024, Keros Therapeutics Inc (NASDAQ:KROS) released its 8-K filing, detailing the company's financial results for the fourth ...
Keros Therapeutics Inc KROS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...